741 related articles for article (PubMed ID: 32369500)
1. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
2. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
[TBL] [Abstract][Full Text] [Related]
3. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
4. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
5. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
[TBL] [Abstract][Full Text] [Related]
6. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
7. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
8. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
[TBL] [Abstract][Full Text] [Related]
9. RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINAL ANGIOMATOUS PROLIFERATION.
Hata M; Yamashiro K; Oishi A; Ooto S; Tamura H; Miyata M; Ueda-Arakawa N; Kuroda Y; Takahashi A; Tsujikawa A; Yoshimura N
Retina; 2017 Nov; 37(11):2069-2077. PubMed ID: 28085772
[TBL] [Abstract][Full Text] [Related]
10. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
Demir N; Sevincli S; Kayhan B; Sonmez M
Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
[TBL] [Abstract][Full Text] [Related]
11. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
[TBL] [Abstract][Full Text] [Related]
12. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results.
Kanesa-Thasan A; Grewal DS; Gill MK; Lyon AT; Mirza RG
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):638-41. PubMed ID: 26114844
[TBL] [Abstract][Full Text] [Related]
14. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
Major JC; Wykoff CC; Croft DE; Wang R; Mariani AF; Lehmann AE; Brown DM
Can J Ophthalmol; 2015 Oct; 50(5):373-7. PubMed ID: 26455973
[TBL] [Abstract][Full Text] [Related]
16. Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration.
Sitnilska V; Altay L; Enders P; Hermann M; Muether PS; Fauser S
Ophthalmologica; 2019; 241(3):154-160. PubMed ID: 30304737
[TBL] [Abstract][Full Text] [Related]
17. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration.
Kim M; Kim ES; Seo KH; Yu SY; Kwak HW
Indian J Ophthalmol; 2016 Jun; 64(6):427-33. PubMed ID: 27488150
[TBL] [Abstract][Full Text] [Related]
18. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.
Fassnacht-Riederle H; Becker M; Graf N; Michels S
Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1705-9. PubMed ID: 24614949
[TBL] [Abstract][Full Text] [Related]
19. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors.
Oliveira MA; Farinha C; Rodrigues TM; Martins A; Cachulo MDL; Marques JP; Pires I; Silva R
Eur J Ophthalmol; 2021 Mar; 31(2):521-528. PubMed ID: 32103681
[TBL] [Abstract][Full Text] [Related]
20. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
